Factor VIII-related antigen-positive microvessel areas were measured by both immunohistochemistry and computerized image analysis in patients with active multiple myeloma (MM), nonactive MM and monoclonal gammopathies of undetermined significance (MGUS). A 5- to 6-fold larger area was found in patients with active MM compared to the other two groups. The conditioned medium (CM) of their bone marrow plasma cells stimulated endothelial cell proliferation and chemotaxis, monocyte chemotaxis and angiogenesis in vivo [chick embryo chorioallantoic membrane (CAM) system] more strongly and frequently than the CM of patients with nonactive MM and MGUS. An immunoassay of plasma cell lysates gave significantly higher levels of fibroblast growth factor-2 (FGF-2) in patients with active MM than in the other two groups, and a neutralizing anti-FGF-2 antibody inhibited by 54–68% the biological activity exerted by the CM in vitro and in the CAM. In situ hybridization of bone marrow plasma cells and gelatin zymography of CM showed that patients with active MM express higher levels of matrix metalloproteinase-2 (MMP-2) mRNA and protein than those with nonactive MM and MGUS, whereas MMP-9 expression and secretion overlapped in all groups. Overall data suggest that patients with active MM represent the vascular phase of plasma cell tumors that is triggered by bone marrow plasma cells, at least partly, through FGF-2 and MMP-2. Both angiogenesis and MMP-2 secretion can account for intramedullary and extramedullary spreading of plasma cells during the active MM.

Keywords:
Angiogenesis, Endothelial cell, Invasion, Metalloproteinases, Multiple myeloma, Tumor progression
1.
Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389–395.
2.
Bonanno E, Iurlaro M, Madri JA, Nicosia RF: Type IV collagen modulates angiogenesis and neovessels survival in the rat aorta model. In Vitro 2000;36:336–340.
3.
Risau W: Mechanisms of angiogenesis. Nature 1997;386:671–674.
4.
Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4–6.
5.
Vacca A, Di Loreto M, Ribatti D, Di Stefano R, Gadaleta-Caldarola G, Iodice G, Caloro D, Dammacco F: Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1 and CD44. Am J Hematol 1995;50:9–14.
6.
Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, Dammacco F: Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503–508.
7.
Geerling S: Kaposi’s sarcoma associated with multiple myeloma. South Med J 1994;77:931–932.
8.
Warner TF, Krueger RG: Perineural angiogenesis in mice bearing subcutaneous tumours. Br J Exp Pathol 1978;59:282–284.
9.
Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R, Albini A, Bussolino F, Dammacco F: Bone marrow neovascularization, plasma cell angiogenic potential and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood 1999;93:3064–3073.
10.
Ohtani H: Stromal reaction in cancer tissue: Pathophysiologic significance of the expression of matrix-degrading enzymes in relation to matrix turnover and immune/inflammatory reaction. Pathol Int 1998;48:1–9.
11.
Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, Presta M: New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: The gelatin sponge/chorioallantoic membrane assay. J Vasc Res 1997;34:455–463.
12.
Menzel T, Rahman Z, Calleja E, White K, Wilson EL, Wieder R, Gabrilove J: Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 1996;87:1056–1063.
13.
Børset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A: Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 1996;271:24655–24661.
14.
Børset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A: Hepatocyte growth factor and its receptor c-met in multiple myeloma. Blood 1996;88:3998–4004.
15.
Seidel C, Børset M, Turesson I, Abildgaard N, Sundan A, Waage A: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998;91:806–812.
16.
Bellamy WT, Richter L, Frutiger Y, Grogan TM: Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Blood 1999;59:728–733.
17.
Portier M, Zhang XG, Ursule E, Lees D, Jourdan M, Bataille R, Kleine B: Cytokine gene expression in human multiple myeloma. Br J Haematol 1993;85:514–520.
18.
Mantovani A, Bussolino F, Dejana E: Cytokine regulation of endothelial cell function. FASEB J 1992;6:2591–2599.
19.
Klein B: Cytokine, cytokine receptors, transduction signals and oncogenes in multiple myeloma. Semin Hematol 1995;32:4–19.
20.
Merico F, Bergui L, Gregoretti MG, Ghia P, Aimo G, Lindley IJD, Calligaris-Cappio F: Cytokines involved in the progression of multiple myeloma. Clin Exp Immunol 1993;92:27–31.
21.
Vacca A, Ribatti D, Iurlaro M, Albini A, Minischetti M, Bussolino F, Pellegrino A, Ria R, Rusnati M, Presta M, Vincenti V, Persico MG, Dammacco F: Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis and angiogenesis. Int J Clin Lab Res 1998;28:55–68.
22.
Huhtala P, Tuuttila A, Chow LT, Lohi J, Keski-Oja J, Tryggvason K: Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kDa enzyme genes in HT-1080 cells. J Biol Chem 1991;266:16485–16490.
23.
Vacca A, Ribatti D, Ria R, Pellegrino A, Bruno M, Merchionne F, Dammacco F: Proteolytic activity of human lymphoid tumor cells. Correlation with tumor progression. Dev Immunol 2000;7:77–88.
24.
Ribatti D, Vacca A, Nico B, Quondamatteo F, Ria R, Minischetti M, Marzullo A, Herken R, Roncali L, Dammacco F: Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer 1999;79:451–455.
25.
Yaccoby S, Barlogie B, Epstein J: Primary myeloma cells growing in SCID-hu mice: A model for studying the biology and the treatment of myeloma and its manifestations. Blood 1998;92:2908–2913.
26.
Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F: Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. Br J Cancer 1999;79:965–970.
27.
Leek RD, Lewis CE, Harris AL: The role of macrophages in tumour angiogenesis; in Bicknell R, Lewis CE, Ferrara N (eds): Tumour Angiogenesis. Oxford, Oxford University Press, 1997, pp 81–89.
28.
Weidner N: Tumoral vascularity as a prognostic factor in cancer patients: The evidence continues to grow. J Pathol 1998;184:119–122.
29.
Hallek M, Bergsagel PL, Anderson KC: Multiple myeloma. Increasing evidence for a multistep transformation process. Blood 1998;91:3–21.
30.
Durie BGM: Staging and kinetics of multiple myeloma; in Wiernik PH, Canellos GP, Kyle RA, Schiffer CA (eds): Neoplastic Diseases of the Blood, ed 2. New York, Churchill Livingstone, 1991, vol 1, pp 439–451.
© 2001 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.